Recently, proton beam therapy (PBT) has gathered attention for improving outcomes and reducing toxicities in various cancers; however, the evidence for esophageal squamous cell carcinoma (ESCC) is lacking. Our study retrospectively evaluated the outcomes of PBT for ESCC patients at a single institute. The patients treated with PBT between November 2015 and February 2022 were included in the study, excluding those with distant metastases or those that had undertaken prior treatment for esophageal cancer (EC). The 3 year overall survival (OS) and progression-free survival (PFS) rates were calculated based on stage grouping. The patterns of failure, salvage treatment outcomes, and toxicity profiles were analyzed. The median follow-up was 35.1 months, and 132 patients were analyzed. The 3 year OS and PFS rates for the stages I, II, and III disease cases were 81.0%, 62.9%, and 51.3%; and 70.6%, 71.8%, and 39.8%, respectively. Nineteen patients presented isolated local progression, ten patients underwent appropriate salvage procedures, and nine were successfully salvaged. One patient with isolated regional progression was also salvaged. No cases of grade ≥ 4 lymphopenia were observed. One patient had grade 4 pericardial effusion and esophageal fistula. For the patients with ESCC, PBT is an effective treatment in terms of the survival outcomes and toxicities.
近年来，质子束治疗因其在多种癌症治疗中改善预后并降低毒副反应而备受关注，然而针对食管鳞状细胞癌的证据尚不充分。本研究回顾性分析了单一机构内食管鳞状细胞癌患者接受质子束治疗的临床结果。研究纳入2015年11月至2022年2月期间接受质子束治疗的患者，排除存在远处转移或既往接受过食管癌治疗的患者。根据分期分组计算三年总生存率和无进展生存率，并对复发模式、挽救性治疗效果及毒性特征进行分析。中位随访时间为35.1个月，共纳入132例患者。I期、II期和III期患者的三年总生存率分别为81.0%、62.9%和51.3%，无进展生存率分别为70.6%、71.8%和39.8%。19例患者出现局部孤立性进展，其中10例接受适当挽救治疗，9例成功获得挽救。1例区域孤立性进展患者亦获成功挽救。未观察到≥4级的淋巴细胞减少症。1例患者出现4级心包积液和食管瘘。对于食管鳞状细胞癌患者，质子束治疗在生存结局和毒性控制方面均显示出良好疗效。
肿瘤(癌症)患者之家